Jubilant Revenues Flat In Q2 On LSI Business Decline, FDA action
LSI To Be Demerged, Founder Cos Merged In Restructuring
Jubilant reports higher second-quarter profits as it defers tax liability while revenues remain flat on the back of a decline in LSI business and FDA action at two manufacturing units.
